Past, present and future in low-risk myelodysplastic syndrome
Myelodysplastic syndromes (MDS) is a heterogeneous group of disorders characterized by increased risk of acute myeloid leukemia transformation and cytopenia. The prognosis of MDS patients can be evaluated with various scoring systems, the most commonly used are IPSS (International Prognostic Scoring...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-07-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2022.967900/full |
| _version_ | 1828264969380036608 |
|---|---|
| author | Selami Kocak Toprak |
| author_facet | Selami Kocak Toprak |
| author_sort | Selami Kocak Toprak |
| collection | DOAJ |
| description | Myelodysplastic syndromes (MDS) is a heterogeneous group of disorders characterized by increased risk of acute myeloid leukemia transformation and cytopenia. The prognosis of MDS patients can be evaluated with various scoring systems, the most commonly used are IPSS (International Prognostic Scoring System), revised-IPSS, and WPSS (WHO classification-based prognostic scoring system). MDS treatment is decided according to the risk classification. The goal of treatment in low-risk MDS is to improve cytopenia, reduce transfusion needs, improve quality of life, prolong overall survival, and maybe reduce the risk of progression to leukemia. In the near future, combining both genomics-based, ex vivo functional based and molecular stratification analysis will lead the way to a personalized and targeted approach. |
| first_indexed | 2024-04-13T04:32:20Z |
| format | Article |
| id | doaj.art-ca3bdde80bcd42ad88e7a17d2b76cea9 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-04-13T04:32:20Z |
| publishDate | 2022-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-ca3bdde80bcd42ad88e7a17d2b76cea92022-12-22T03:02:17ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2022-07-01910.3389/fmed.2022.967900967900Past, present and future in low-risk myelodysplastic syndromeSelami Kocak ToprakMyelodysplastic syndromes (MDS) is a heterogeneous group of disorders characterized by increased risk of acute myeloid leukemia transformation and cytopenia. The prognosis of MDS patients can be evaluated with various scoring systems, the most commonly used are IPSS (International Prognostic Scoring System), revised-IPSS, and WPSS (WHO classification-based prognostic scoring system). MDS treatment is decided according to the risk classification. The goal of treatment in low-risk MDS is to improve cytopenia, reduce transfusion needs, improve quality of life, prolong overall survival, and maybe reduce the risk of progression to leukemia. In the near future, combining both genomics-based, ex vivo functional based and molecular stratification analysis will lead the way to a personalized and targeted approach.https://www.frontiersin.org/articles/10.3389/fmed.2022.967900/fullmyelodysplastic syndromelow risktreatmentanemiathrombocytopenia |
| spellingShingle | Selami Kocak Toprak Past, present and future in low-risk myelodysplastic syndrome Frontiers in Medicine myelodysplastic syndrome low risk treatment anemia thrombocytopenia |
| title | Past, present and future in low-risk myelodysplastic syndrome |
| title_full | Past, present and future in low-risk myelodysplastic syndrome |
| title_fullStr | Past, present and future in low-risk myelodysplastic syndrome |
| title_full_unstemmed | Past, present and future in low-risk myelodysplastic syndrome |
| title_short | Past, present and future in low-risk myelodysplastic syndrome |
| title_sort | past present and future in low risk myelodysplastic syndrome |
| topic | myelodysplastic syndrome low risk treatment anemia thrombocytopenia |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2022.967900/full |
| work_keys_str_mv | AT selamikocaktoprak pastpresentandfutureinlowriskmyelodysplasticsyndrome |